Vanda Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $656.2 Mil.
During the past 12 months, Vanda Pharmaceuticals's average Total Assets Growth Rate was 8.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 20.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 20.10% per year.
During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 113.30%. The lowest was -9.70%. And the median was 18.35%.
Vanda Pharmaceuticals Total Assets Historical Data
The historical data trend for Vanda Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Vanda Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (NAS:VNDA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Vanda Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Vanda Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VNDA has been successfully added to your 